Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.

One down, two more to go. Celltrion seals a formulary deal with one of the top three PBMs in the US for its subcutaneous infliximab product Zymfentra.

The pool of prospective Xolair biosimilars is small, with only Teva and Kashiv BioSciences/Alvotech disclosing Phase III comparison trials for their biosimilar products. Ahead of them in the pack, Celltrion has just taken a giant stride towards the first pan-European marketing approval.

With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.